Wojdas, M.; Dąbkowska, K.; Kuźnik-Trocha, K.; Wisowski, G.; Lachór-Motyka, I.; Komosińska-Vassev, K.; Olczyk, K.; Winsz-Szczotka, K.
Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction. Biomedicines 2022, 10, 1845.
https://doi.org/10.3390/biomedicines10081845
AMA Style
Wojdas M, Dąbkowska K, Kuźnik-Trocha K, Wisowski G, Lachór-Motyka I, Komosińska-Vassev K, Olczyk K, Winsz-Szczotka K.
Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction. Biomedicines. 2022; 10(8):1845.
https://doi.org/10.3390/biomedicines10081845
Chicago/Turabian Style
Wojdas, Magdalena, Klaudia Dąbkowska, Kornelia Kuźnik-Trocha, Grzegorz Wisowski, Iwona Lachór-Motyka, Katarzyna Komosińska-Vassev, Krystyna Olczyk, and Katarzyna Winsz-Szczotka.
2022. "Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction" Biomedicines 10, no. 8: 1845.
https://doi.org/10.3390/biomedicines10081845
APA Style
Wojdas, M., Dąbkowska, K., Kuźnik-Trocha, K., Wisowski, G., Lachór-Motyka, I., Komosińska-Vassev, K., Olczyk, K., & Winsz-Szczotka, K.
(2022). Plasma Glycosaminoglycans in Children with Juvenile Idiopathic Arthritis Being Treated with Etanercept as Potential Biomarkers of Joint Dysfunction. Biomedicines, 10(8), 1845.
https://doi.org/10.3390/biomedicines10081845